Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Sangamo Biosciences Inc (SGMO)  
$0.52 0.04 (6.83%) as of 4:30 Wed 4/10


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 140,990,000
Market Cap: 73.88(M)
Last Volume: 2,041,307 Avg Vol: 1,748,484
52 Week Range: $0.2971 - $1.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 11,784
Total Buy Value $0 $0 $0 $43,025
Total People Bought 0 0 0 2
Total Buy Transactions 0 0 0 2
Total Shares Sold 0 0 6,000,000 6,500,000
Total Sell Value $0 $0 $3,000,000 $5,657,240
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 3
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 1096
  Page 17 of 44  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gregory Philip D SVP of Research & CSO   •       –      –    2015-03-02 4 OE $3.45 $110,120 D/D 15,000 131,410     -
   Lanphier Edward O Ii President & CEO   •       •      –    2015-02-17 4 AS $15.69 $392,150 D/D (25,000) 235,000     -
   Lanphier Edward O Ii President & CEO   •       •      –    2015-02-17 4 OE $6.82 $170,500 D/D 25,000 260,000     -
   Ramasastry Saira Director   –       •      –    2015-02-12 4 AS $15.00 $150,000 D/D (10,000) 0     -
   Ramasastry Saira Director   –       •      –    2015-02-12 4 OE $5.03 $50,300 D/D 10,000 10,000     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2015-02-10 4 AS $12.63 $151,750 D/D (12,000) 206,849     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2015-02-10 4 OE $3.45 $34,500 D/D 10,000 218,849     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2015-02-05 4 AS $12.93 $193,950 D/D (15,000) 95,376     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2015-02-05 4 OE $3.45 $91,509 D/D 15,000 110,376     -
   Ringo William R Director   –       •      –    2015-02-03 4 AS $12.70 $27,940 D/D (2,200) 800     -
   Ringo William R Director   –       •      –    2015-02-03 4 OE $6.41 $14,102 D/D 2,200 3,000     -
   Gregory Philip D SVP of Research & CSO   •       –      –    2015-02-02 4 AS $12.86 $192,830 D/D (15,000) 116,410     -
   Gregory Philip D SVP of Research & CSO   •       –      –    2015-02-02 4 OE $3.45 $77,000 D/D 15,000 131,410     -
   Lanphier Edward O Ii President & CEO   •       •      –    2015-01-16 4 AS $14.29 $142,853 D/D (10,000) 235,000     -
   Lanphier Edward O Ii President & CEO   •       •      –    2015-01-16 4 OE $6.82 $68,200 D/D 10,000 245,000     -
   Lanphier Edward O Ii President & CEO   •       •      –    2015-01-15 4 AS $14.09 $212,769 D/D (15,000) 235,000     -
   Lanphier Edward O Ii President & CEO   •       •      –    2015-01-15 4 OE $6.82 $102,300 D/D 15,000 250,000     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2015-01-12 4 AS $15.87 $190,450 D/D (12,000) 208,849     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2015-01-12 4 OE $3.45 $34,500 D/D 10,000 220,849     -
   Ringo William R Director   –       •      –    2015-01-05 4 S $15.20 $33,430 D/D (2,200) 800     -
   Ringo William R Director   –       •      –    2015-01-05 4 OE $6.41 $14,102 D/D 2,200 3,000     -
   Larson John William Director   –       •      –    2015-01-05 4 AS $15.10 $226,550 D/D (15,000) 214,660     -
   Larson John William Director   –       •      –    2015-01-05 4 OE $5.03 $102,850 D/D 15,000 229,660     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2015-01-05 4 AS $15.17 $227,854 D/D (15,000) 95,376     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2015-01-05 4 OE $6.82 $102,300 D/D 15,000 110,376     -
  1096 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 17 of 44
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us